Guggenheim analyst Michael Schmidt raised the firm’s price target on BeOne Medicines (ONC) to $420 from $410 and keeps a Buy rating on the shares after the company reported a topline beat in Q1 accompanied by a raise of 2026 guidance. The firm is updating its model to reflect Q1 results and guidance, calling BeOne its mid-cap top pick.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines reports Q1 adjusted EPS $3.24 vs. $1.22 last year
- BeOne Medicines raises FY26 revenue view to $6.3B-$6.5B from $6.2B-$6.4B
- AMD downgraded, Airbnb upgraded: Wall Street’s top analyst calls
- BeOne Medicines initiated with an Overweight at Wells Fargo
- BeOne Medicines: FDA grants Priority Review to sBLA for tevimbra/ziihera combo